FDA Novel Switch Meeting Shows Gulf Between Interests

This article was originally published in The Pink Sheet Daily

28 Mar 2012
News

Malcolm Spicer @TheTanSheet malcolm.spicer@informa.com

Executive Summary

Drug manufacturers and physicians are at odds with the pharmacy industry’s expectations for the role pharmacists will have in distributing novel switches. At an FDA public hearing, CDER Director Janet Woodcock says the agency expects to “extend the concept of self-diagnosis and self-treatment to additional drugs.”

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

United States

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Consumer Medical Device

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS073943

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS073943

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

FDA Novel Switch Meeting Shows Gulf Between Interests

News

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert